📒 Six years of collaboration, now captured in one publication!
🌟 Coordinated by IrsiCaixa, the European project @mistralhiv presents its final brochure highlighting key outcomes and impact.
👀 Take a look: https://t.co/RvUTgkiurQ
🎉We’re excited to share our final brochure! It highlights the results and achievements of MISTRAL over these years.
You can find it on our website in the Resources section. Check it out!👉https://t.co/nVfIrILIUC
The #MISTRAL team wishes our partners, followers and those who have been following our activities during these 5 years a good holiday season and a happy new year 🎄 🎉
🗞️A new research paper led by our partner @idibaps found that in people with very advanced #HIV, the DTG-based treatment worked faster, was safe, and reduced signs of inflammation better than the DRV/r-based treatment. Read further 👇
https://t.co/b6C5oTXXqC
👩🔬New research in MISTRAL from Kristina Broliden’s group @karolinskainst shows the cervicovaginal microbiome affects cervical gene activity, Lactobacillus-rich #microbiomes strengthen the mucosal barrier, diverse ones may weaken it, influencing #HIV risk.👇https://t.co/UH5pywj7gQ
🪢 On #WorldAIDSDay, #IrsiCaixa and @FundlaCaixa present 🟥 RED, a documentary with real testimonies and scientific perspectives to better understand #HIV through memory, stigma and future challenges.
🎬 From today, available for free on CaixaForum+.
👉🏽 https://t.co/5efhiOpkHP
🔬🚀 What a great scientific journey it is to coordinate the MISTRAL European project.
Today we’re holding its final Annual Meeting, and we couldn’t be prouder of all the achievements we’ve accomplished together. 🤝
📢We kicked off the first day of the last MISTRAL Annual Meeting today, exchanging updates and insights on our most recent project accomplishments.👇
#Microbiome#HIV
🦠Antimicrobial resistance (#AMR) happens when bacteria, viruses, fungi, and parasites stop responding to medicines. When drugs stop working, common infections can become dangerous or even untreatable.⚠️
#AMRAwarenessWeek
Lately another study from MISTRAL found that Zidovudine, Efavirenz and Elvitegravir have antibacterial activity against Prevotella bivia. Read further here 👉https://t.co/uwyQeZLz1I
🦠Meet Prevotella, a genus of bacteria that is gram-negative, anaerobic and rod-shaped commonly found in the human mouth, gastrointestinal tract and female genial tract. Prevotella plays both beneficial and harmful roles depending on their environment.
#Bacteria#MeetTheMicrobes
Another study from MISTRAL has found that certain levels of neutralizing antibody responses were correlated with abundance of Prevotella in skin. Read further here 👉https://t.co/y08GTuCq2G
Researchers have found differences in lung microbiota between HIV+ and non-HIV patients with Pneumocystis jirovecii infection, which may explain divergent clinical outcomes. Read further about it👇
https://t.co/mHjS3bltKX
#InfectiousDiseases#HIV
A new study reveals gut microbiota dysbiosis in people living with HIV (PLWH) who develop cancer. Some key finidings show that Bacteroides depletion is linked to cancer-related metabolic pathways. Read further about it 👉 https://t.co/VdYuK2QxoD
#Microbiome#HIV#CancerResearch
🦠Currently HIV is a chronic disease, however immune activation and inflammation persist. Recent research shows the gut microbiome, especially short-chain fatty acids, could be key to reducing these effects. Read further about it👉https://t.co/2cUqcCeOKv
#HIV#GutHealth
MISTRAL has found that Elvitegravir, an antiretroviral drug, has antibacterial activity against methicillin-resistant Staphylococcus aureus strains. Read further👉
https://t.co/uwyQeZLz1I
🦠Meet Staphylococcus aureus a gram-positive species that can be found on our skin and nasal phages. While it is usually harmless, sometimes can cause infections.
🦠💊 A new review explores why the gut matters for HIV cure research and explores emerging therapies like latency reversal, immune modulation and gut-targeted ART. Read further here 👇
https://t.co/d6Iaqp72nl
#HIV#Gut